Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
Sell
-1,900
Closed -$519K 174
2017
Q1
$519K Buy
+1,900
New +$537K 0.1% 194
2015
Q4
Sell
-1,500
Closed -$438K 163
2015
Q3
$438K Sell
1,500
-3,700
-71% -$1.22M 0.15% 70
2015
Q2
$2.1M Buy
5,200
+4,700
+940% +$1.89M 0.8% 26
2015
Q1
$211K Sell
500
-1,000
-67% -$394K 0.11% 162
2014
Q4
$509K Buy
+1,500
New +$485K 0.21% 69
2014
Q3
Sell
-3,300
Closed -$1.04M 204
2014
Q2
$1.04M Sell
3,300
-3,600
-52% -$1.08M 0.5% 38
2014
Q1
$2.11M Buy
+6,900
New +$2.19M 0.47% 33

Other funds holding BIIB

QCM Cayman's BIIB Position: Q1 2021 in Review

QCM Cayman sold out of Biogen (BIIB) in Q1 2021, closing a stake of 897 shares — an estimated $220K sold.

QCM Cayman first reported a position in BIIB in Q4 2013 and held it in 7 quarters. The position peaked at $726K in Q3 2015. 1,094 funds tracked by Wall St. Rank hold BIIB as of Q1 2021.

  • QCM Cayman reported no remaining Biogen position as of Q1 2021 after selling out during the quarter.
  • QCM Cayman sold 897 Biogen shares in Q1 2021, an estimated $220K.
  • QCM Cayman first reported a position in Biogen in Q4 2013 and held it in 7 quarters.
  • QCM Cayman's Biogen position peaked at $726K in Q3 2015.
  • 1,094 funds tracked by Wall St. Rank held Biogen as of Q1 2021.

Based on QCM Cayman's 13F filing for Q1 2021, filed 17 May 2021.